PLSENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PULSE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$47.55+3.12 (+7.02%)
Close on Oct 19, 2026
- Market cap
- $3.29B
- P/E (TTM)
- –
- Dividend yield
- –
PULSE BIOSCIENCES, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Cycle Units Products [Member] | $0 | $140.00K | $229.00K | $0 | – | -100.0% |
| System Products [Member] | $0 | $560.00K | $1.19M | $0 | – | -100.0% |
| Product [Member] | – | $700.00K | $1.42M | $0 | – | – |
| Systems Products [Member] | – | – | $1.19M | – | – | – |
By region
| Revenue | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| North America [Member] | $0 | $517.00K | $1.18M | $0 | – | -100.0% |
| Rest of World [Member] | $0 | $183.00K | $236.00K | $0 | – | -100.0% |
| Rest Of World [Member] | – | – | $236.00K | – | – | – |
From the segment and revenue-disaggregation notes of Pulse Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.